Hoffmann-la Roche Inc.

Roche Glycart Ag

Cuiying Shao

Ekkehard Moessner

Christian Klein

Lei Shi

Pablo Umana

Peng Wang

Ralf Hosse

Jens Niewoehner

Petra Rueger

Georg Tiefenthaler

Juergen Michael Schanzer

Gang Xu

Adrian Hugenmatter

Katharina Wartha

Francesca Ros

Herein is reported a blood brain barrier shuttle module comprising a brain effector entity, a linker and one monovalent binding entity which binds to a blood brain barrier receptor, wherein the linker couples the effector entity to the monovalent binding entity which binds to the blood brain barrier receptor wherein the monovalent binding entity does not comprise the variable domains of the anti-transferrin receptor antibody 8D3 (SEQ ID NO: 01 and SEQ ID NO: 02) or of the variant anti-transferrin receptor antibody 8D3v (SEQ ID NO: 01 and SEQ ID NO: 03).

Monovalent blood brain barrier shuttle modules

The present invention relates to bispecific anti-EGFR/anti IGF-1R antibodies, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.

Bispecific anti-EGFR/anti IGF-1R antibodies

Growing community of inventors

Shanghai, China

Cuiying Shao